Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cycrimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 9/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 1/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 1/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trihexyphenidyl SCHEMBL1320615 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| (R)-Procyclidine SCHEMBL15305878 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Cycrimine SCHEMBL249004 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL34646 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL34645 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Procyclidine SCHEMBL147344 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| (S)-Procyclidine SCHEMBL519431 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Procyclidine SCHEMBL121684 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL42410 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL30061697 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302814-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-10-02 | — | — | US | claimed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4543431-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) (US) | 2025-04-30 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240358709-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2024-10-31 | — | — | US | claimed |
| US-20240261239-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-08-08 | — | — | US | claimed |
| EP-4395721-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2024-07-10 | — | — | EP | claimed |
| US-20240189328-A1 | COMBINATION OF NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2024-06-13 | — | — | US | claimed |
| US-20240189261-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-06-13 | — | — | US | claimed |
| WO-2007075396-A2 | METHODS AND DEVICES TO CURB APPETITE AND/OR REDUCE FOOD INTAKE | ENDOSPHERE, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060178691-A1 | Methods and devices to curb appetite and/or reduce food intake | THE DIRECTOR OF DEVELOPMENT OF THE STATE OF OHIO | 2006-08-10 | — | — | US | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CHRM1 3667/4885CHRM2 2986/4885CYP2D6 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.